Kun elektronisk udgave - Sundhedsstyrelsen

More documents

Recommendations

Info

Ruskovic D, Ulbig MW, Rothbachen HH et al. IOVS 1996;37:p 131. (80)Scheider A, Gündisch O, Kampik A. Surgical extraction of subfovealchoroidal new wessels and submacular hemorrhage in age-related maculardegeneration: results of a prospective study. Graefes Arch Clin Exp Ophthalmol1999;237:10-15. (81)Scott IU, Smiddy WE, Schiffman J et al. Quality of life of low-visionpatients and the impact of low-vision services. Am J Ophthalmol 1999;128:54-62. (82)Seland JH et al. Photodynamic therapy for age-related macular degeneration.The Norwegian Centre for Health Technology Assessment (SMM)2000 (SMM-Report 3/2000) (83).Seddon JM, Ajani UA, Sperduto RD. Dietary caretenoids, vitamin A,Cand E and advanced age-related macualr degeneration. JAMA 1994;272:1413-1420. (84)Seo MS, Kwak N, Ozaki H et al. Dramatic inhibition of retinal and choroidalneovascularization by oral administration of a kinase inhibitor. Am JPathol 1999;154(6):1743-53. (85)Sickenberg M, Schmidt-Erfurth U, Miller JW et al. A preliminary study ofphotodynamic therapy using Verteporfin for choroidal neovascularizationin pathologic myopia, ocular histoplasmosis syndrome, angioid streaksand idiopatic causes. Arch Ophthalmol 2000;118:327-336. (86)Singermann L. VIP 12-months topline data.Http://www.visudyne.wwwebposium.com/pw/html/index.html (87)Smiddy WE, Fine SL. Prognosis of patients with bilateral macular drusen.Ophthalmology 1984;91:271-277. (88)Steinberg EP, Tielch JM, Schein OD et al. The VF-14: an index of functionalimpairment in patients with cataract. Arch Ophthalmol 1994;112::195-203. (89)Stur M, Tittl M, Reitner A, Meisinger V. Oral zinc and the second eye inage-related macular degeneration. IOVS 1996;37:1225-1235. (90)Swedish Council on Technology Assessment in Health Care. Photodynamictreatment for macular degeneration – early assessment (ALERT) 2000. (91)Takehana Y, Kurokawa T, Kitamura T et al. Suppression of laser-inducedchoroidal neovascularization by oral Tranilast in the rat. IOVS 1999;40:459-466. (92)TAP Study Group. Photodynamic Therapy of Subfoveal Choroidal Neovascularizationin Age-related Macular Degeneration with Verteporfin. ArchOphthalmol 1999;117:1329-1345. (93)85
TAP Study Group. Photodynamic Therapy of Subfoveal Choroidal Neovascularizationin Age-related Macular Degeneration with Verteporfin. ArchOphthalmol 2001;119:198-207. (94)Thomas MA, Grand MG, Williams DF. Surgical extraction of subfovealchoroidal neovascularization. Ophthalmology 1992;99:952-68. (95)Vinding T. Age-related macular degeneration: Macular changes, prevalenceand sex ration. An epidemiologic study of 1000 aged individuals.Acta Ophthalmol 1989;67:609-616. (96)Vingerling JR, Hofman A, Grobbee DE. Age-related macular degenerationand smoking: The Rotterdam study. Arch Ophthalmol 1996; 114:1193-1196. (97)Vingerling JR, Hofman A, Klaver CC. Smoking is also associated withage-related macular degeneration in persons aged 85 years and older: TheRotterdam Study.Letter. Arch Ophthalmol 1997;115:945. (98)Wallow IH. Repair of the pigment epithelial barrier following photocoagulation.Arch Ophthalmol 1984;102:126-135. (99)Williams RA, Brody BL, Thomas RG et al. The psychosocial impact ofmacular degeneration. Arch Ophthalmol 1998;116(4):514-20. (100)West S, Vitale S, Hallfrisch J et al. Are antioxidants or supplements protectivefor age-related macular degeneration? Arch Ophthalmol 1994;112:222-227. (101)Wormald R et al. Photodynamic therapy for neovascular age-related maculardegeneration (Cochrane Review) In : The Cochrane Library, Issue 3,2002. (102)Yanoff M, Duker JS. Ophthalmology. Mosby International Ltd. P. 1999.(103)86
Page 2 and 3:
Fotodynamisk behandling afkarnydann
Page 9 and 10:
som rammer erhvervsaktive yngre men
Page 12 and 13:
1IntroduktionAldersrelateret macula
Page 14:
som følge af AMD - vil nå op på
Page 17 and 18:
pension af lipidomsluttede mikrosf
Page 19 and 20:
hos 61% af de behandlede patienter,
Page 22 and 23:
3PatientenGrundsygdommen ARM medfø
Page 24:
nelse, helt op til 87% inden for 5
Page 27 and 28:
TABEL 1Personaletimer pr. behandlin
Page 29 and 30:
man derfor antager, at de fleste pa
Page 31 and 32:
eview af litteratur om incidens af
Page 33 and 34:
ehandlede vil have et større overs
Page 35 and 36: ode bevirker diskontering, at forho
Page 37 and 38: sidste rest af centralsyn svinder p
Page 39 and 40: give en behandling med en relativt
Page 42 and 43: 7Ordliste, anvendte forkortelser og
Page 44: QALYretinaserøsstromasubfovealsubr
Page 47 and 48: Communities Study, fandt man en hø
Page 49 and 50: Når AMD medfører symptomer, er de
Page 51 and 52: Bilag 2Eksperimentelle eller uvalid
Page 53 and 54: tion af antioksidanter og zink. Der
Page 55 and 56: TermoterapiI mindre, ukontrollerede
Page 57 and 58: Bilag 3Epidemiologi: Tidligere stud
Page 59 and 60: Bilag 4Incidensopgørelse af potent
Page 61 and 62: henvist til vurdering i hospitalsre
Page 63 and 64: patientbetingede grænser for hvor
Page 65 and 66: Bilag 5Syn, funktionsevne og helbre
Page 67 and 68: den), afstandssynet (Snellen’s bo
Page 69 and 70: ste øje, eller et sammenligneligt
Page 71 and 72: Bilag 6Produktinformation (ved Nova
Page 73 and 74: Udtrængning fra karsystemet (ektra
Page 75 and 76: under ”Særlige advarsler og fors
Page 77 and 78: ProteinbindingI humant fuldblod fin
Page 79 and 80: fortyndes med 5% Glucose til injekt
Page 81 and 82: Blumenkranz MS. Status of photodyna
Page 83 and 84: Klein R, Clegg C, Cooper LS et al.
Page 85: MPSG. Subfoveal neovascular lesions
show all

Kun elektronisk udgave - Sundhedsstyrelsen

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?